Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 5/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.36 |
| ▸ | CCR5 | P51681 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19273240 | 0.97 | CHRM4 (0.49) | CHRM4CHRM2CHRM1CCR5KMT2A | |
| SCHEMBL18429043 | 0.89 | CHRM4 (0.52) | CHRM4CHRM2CHRM1KMT2ASMN1; SMN2 | |
| SCHEMBL18429044 | 0.85 | CHRM4 (0.49) | CHRM4CHRM2CHRM1KMT2ASMN1; SMN2 | |
| SCHEMBL18429004 | 0.83 | CHRM4 (0.50) | CHRM4CHRM2CHRM1KMT2ASMN1; SMN2 | |
| SCHEMBL18428974 | 0.83 | CHRM4 (0.52) | CHRM4CHRM2CHRM1CCR5KMT2A | |
| SCHEMBL18429018 | 0.81 | CHRM4 (0.51) | CHRM4CHRM2CHRM1SMN1; SMN2LMNA | |
| SCHEMBL22797833 | 0.81 | CHRM4 (0.41) | CHRM4CHRM2CHRM1CCR5ALDH1A1 | |
| SCHEMBL18428926 | 0.81 | CHRM4 (0.52) | CHRM4CHRM2CHRM1KMT2ASMN1; SMN2 | |
| SCHEMBL22813523 | 0.80 | CHRM4 (0.57) | CHRM4CHRM2CHRM1SMN1; SMN2L3MBTL1 | |
| SCHEMBL23368251 | 0.80 | CHRM4 (0.51) | CHRM4CHRM2CHRM1SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385039-B2 | Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-08-20 | — | — | US | disclosed |
| US-20190112294-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARNIC M1 RECEPTOR AND/OR M4 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2019-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112294-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARNIC M1 RECEPTOR AND/OR M4 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | CHRM4 4/4885CHRM2 2/4885CHRM1 1/4885 |
| US-10385039-B2 | Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonists | CHRM1, CHRM2, CHRM5 | CHRM4 4/4885CHRM2 2/4885CHRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.